



What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

Sébastien Reig, Audrey Le Gouellec, Sophie Bleves

► To cite this version:

Sébastien Reig, Audrey Le Gouellec, Sophie Bleves. What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?. *Frontiers in Cellular and Infection Microbiology*, 2022, 12, 10.3389/fcimb.2022.909731 . hal-03781230

HAL Id: hal-03781230

<https://amu.hal.science/hal-03781230>

Submitted on 20 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

What's new in the anti-*Pseudomonas aeruginosa* clinical development pipeline since the 2017 WHO alert?

Sébastien Reig^{1*}, Audrey Le Gouellec², Sophie Bleves^{1*}

¹Laboratoire d'Ingénierie des Systèmes Macromoléculaires (LISM), Institut de Microbiologie, Bioénergies et Biotechnologie (IM2B), Aix-Marseille Université-CNRS, UMR7255, Marseille, France.

²Laboratoire Techniques de l'Ingénierie Médicale et de la Complexité (UMR5525), Centre National de la Recherche Scientifique, Université Grenoble Alpes, VetAgro Sup, Grenoble INP, CHU Grenoble Alpes, Grenoble, France.

* Correspondence:

Sébastien Reig

sreig@imm.cnrs.fr

Sophie Bleves

bleves@imm.cnrs.fr

ABSTRACT

The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) are considered “critical-priority” bacteria by the World Health Organization (WHO) since 2017 taking into account criteria such as patient mortality, global burden disease and worldwide trend of multi-drug resistance (MDR). Indeed *P. aeruginosa* can be particularly difficult to eliminate from patients due to its combinatorial antibiotic resistance, multifactorial virulence and ability to over-adapt in a dynamic way. Research is active but the course to a validated efficacy of a new treatment is still long and uncertain. What's new in the anti-*P. aeruginosa* clinical development pipeline since the 2017 WHO alert? This review focuses on new solutions for *P. aeruginosa* infections that are in active clinical development, i.e., currently being tested in humans and may be approved for patients in the coming years. Among 18 drugs of interest in December 2021 anti-*P. aeruginosa* development pipeline described here, only one new combination of β -lactam/ β -lactamase inhibitor is in phase III trial. Derivatives of existing antibiotics considered as “traditional agents” are over-represented. Diverse “non-traditional agents” including bacteriophages, iron mimetic/chelator and anti-virulence factors are significantly represented but unfortunately still in early clinical stages. Despite decade of efforts, there is no vaccine currently in clinical development to prevent *P. aeruginosa* infections. Studying pipeline anti-*P. aeruginosa* since 2017 up to now, shows how to provide a new treatment for patients can be a difficult task. Given the process duration, the clinical pipeline remains unsatisfactory leading best case to the approval of new antibacterial drugs that treat CRPA in several years. Beyond investment needed to build a robust pipeline, the Community needs to reinvent medicine with new strategies of development to avoid the disaster. Among “non-traditional agents”, anti-virulence strategy may have the potential through novel and non-killing modes of action to reduce the selective pressure responsible of MDR.

Keywords: *Pseudomonas aeruginosa*, multi-drug resistance, development pipeline, vaccine, immunotherapy, antibiotics, phage therapy, anti-virulence strategy.

INTRODUCTION

As a worldwide public health threat, the World Health Organization (WHO) established a list of antibiotic-resistant bacteria in 2017 (Tacconelli et al., 2018). The aim was to prioritize and stimulate research and development strategies of new active drugs. Among relevant criteria such as patient mortality prevalence, health-care burden and trend of resistance worldwide, carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) were considered “critical-priority” bacteria (Tacconelli et al., 2018). Indeed, Carbapenem antibiotics are reserved for the treatment of multi-drug resistant (MDR) bacterial infections and when bacteria develop resistance to them, treatment options become extremely limited.

P. aeruginosa is an opportunistic pathogen responsible for both severe acute and chronic infections, and is a significant cause of healthcare-associated infections, particularly in critically ill and immunocompromised patients (**Figure 1**). Since its first description in wound infections (Gessard, 1882), *P. aeruginosa* is now a well-known pathogen. Pathogenesis of *P. aeruginosa* is mediated by an arsenal of virulence factors: motility, adherence to biotic and abiotic surfaces, secreted toxins also called effectors that are released in the environment or injected into host cells or other bacteria (**Figure 2**). These effectors are able to modulate or disrupt host cells signaling pathways, target extracellular matrix, induce tissue damage and shape the local microbiome by competition (**Figure 2**). The ability of *P. aeruginosa* to form a biofilm is also a key factor that increases drug resistance, escape from host defense and is responsible for colony tolerance to disinfectants on medical devices (Jurado-Martín et al., 2021; Pang et al., 2019; Mulcahy et al., 2014). As all these factors contribute to pathogenicity by complementary actions, *P. aeruginosa* is characterized by a combinatorial multifactorial virulence. Moreover, multiple mechanisms of antibiotic resistance have been identified, including intrinsic membrane permeability, drug efflux systems, production of antibiotic-inactivating enzymes and loss of porin function (Pang et al., 2019). Finally, the plasticity of its (i) virulence factor gene expression, (ii) antibiotic resistance and (iii) metabolism in response to selective pressure is one of the most challenging feature of *P. aeruginosa* allowing the transition from acute to chronic infections. Acute infections are mainly associated with planktonic life style, while biofilm plays a major role in persistent infections. This remarkable ability of over-adaptation in a dynamic way allows this pathogen to escape immune system and become multi drug resistant or extensively drug resistant (XDR). Once a chronic infection in the patient is established, *P. aeruginosa* is really difficult to treat.

To meet this major treatment issue, research is active with a variety of approaches ranging from disarming the pathogen with an anti-virulence strategy to eliminating it. In parallel with the growing knowledge of the molecular mechanisms of *P. aeruginosa*-host interaction, the number of potential therapeutic targets is increasing. However, the path to validate efficacy of a new drug in Human is long and uncertain. Two antibacterial tracks of development are followed and consist in “traditional agents” (small molecule directly targeting the bacterium for a bacteriostatic or bactericidal action) and new therapeutics called “non-traditional” (large molecule and/or not acting by directly targeting bacterial components essential for bacterial growth). Characterized by new, non-bactericidal, and generally species-specific modes of action, the paradigm is that non-traditional agents are less likely to generate the dreaded resistance (Tse et al., 2017). Indeed a non-killing agent reduce the selective pressure and its specificity avoid cross-resistance potentially induced by horizontal genes transfer (Tse et al., 2017). This review focuses on new solutions for *P. aeruginosa* infections that are in active clinical development, i.e., currently being tested in humans and may be approved for patients in the coming years. A literature search was performed in a context of need to address clearly the question: what’s new in the anti-*P. aeruginosa* clinical development pipeline since the 2017 WHO alert?

RATIONALE OF THIS REVIEW AND METHODOLOGY OF DATA SEARCH

With more than 74,000 articles published in PubMed® in December 2021, knowledge about *P. aeruginosa* is growing in the fields of its virulence, antibiotic resistance, lifestyle, metabolism, clinical manifestations, clinical or observational studies, health and economic burden, among others. Numerous articles or reviews detail the potential new targets from basic research, the emerging new candidate therapies in early phase, or the pipeline of antibacterial molecules in preclinical and clinical testing and the hope that comes with it (Burrows, 2018; Tümmler, 2019; WHO, 2019; Theuretzbacher et al., 2020; WHO, 2021; Yaeger et al., 2021). It is difficult to find one's way through all this data, which is often mixed and rarely dedicated to *P. aeruginosa*. It is important to keep in mind that before proof of concept in a phase II study, no efficacy is proven in patients. Efficacy-safety balance evaluation in *P. aeruginosa* infected patients is an unavoidable milestone. To dedicate this review only to anti-*P. aeruginosa* treatments in clinical development, a literature search was conducted with a specific strategy in the PubMed® database between January 2017 and December 2021. The following criteria were used: (i) keywords related to development (antibacterial pipeline, antibiotic pipeline, clinical development) and treatment (drug, antibiotic, therapy), (ii) selection of phase I to III clinical trials, and (iii) exclusion of research data or preclinical targets (**Figure 3**). Clinical trial registries and websites of companies or organizations with a special interest in the field were consulted to verify or supplement the data (**Figure 3**).

VACCINES: A PROPHYLACTIC STRATEGY FOR HIGH-RISKS PATIENTS

A vaccine against *P. aeruginosa* for at-risk patients (i.e., those older than 65 years, those with cystic fibrosis (CF), bronchiectasis, or chronic obstructive pulmonary disease) could reduce the prevalence of infections, the overall burden disease, and the use of antibiotic treatment. Therefore, although formal data are lacking, the vaccine, by limiting the use of antibiotics and thus reducing selection pressure on pathogens, has a significant indirect impact on the emergence of antibiotic resistance (Micoli et al., 2021; López-Siles et al., 2021). An important challenge for obtaining a good vaccine is the identification of ideal antigens, i.e. antigens accessible or presented to the immune system, adequately immunogenic and highly conserved across all serotypes (Sainz-Mejías et al., 2020), regardless of the stage or location of the infection. Antigen variability, plasticity of virulence factor expression during acute to chronic infection described earlier in the introduction, and bacterial localization (the mucosal immune response is compromised in dehydrated and sticky mucus in lungs of CF patients) are a challenge. In addition, it is also necessary to find a safe but immunogenic vector and antigen formulation (with or without adjuvant), allowing mucosal vaccination, intracellular and extracellular delivery of antigens to achieve specific cellular and humoral immunity, as well as long-term immunity. Finally, the choice of the target pathology is also very important: bacteremia, chronic lung infection, keratitis, urinary tract or skin infection for the clinical trial.

Despite active research for a *P. aeruginosa* vaccine during over half a century, no vaccine has yet been approved (Sainz-Mejías et al., 2020; López-Siles et al., 2021; Micoli et al., 2021). Several antigens (lipopolysaccharide LPS, alginate, flagellum, type 4 pili, outer membrane proteins OMPs, type 3 secretion systems T3SS, T2SS effectors, autoinducers, iron-uptake proteins) have been targeted in clinical development, but to date only three vaccines reached the phase III trials (Rello et al., 2017). The investigational vaccine IC43, a recombinant OMPs (OprF porin/OprI lipoprotein)-based vaccine, appeared to be the last promising based on the favorable safety and immunogenicity profile from phase II study (Adlbrecht et al., 2020).

But what's new in the clinical development pipeline since the 2017 WHO alert?

Results from a phase II/III, multicenter, randomized, placebo-controlled, double-blinded confirmatory study of IC43 vaccine against *P. aeruginosa* were published in 2020 (Adlbrecht et al., 2020). 799 patients requiring mechanical ventilation received the vaccine at the time of admission to the intensive care unit (ICU). Although the study confirmed the safety profile and immunogenicity, the primary endpoint was not met with the IC43 vaccine providing no clinical benefit over placebo in terms of overall mortality (29.2% versus 27.7% in the IC43 and placebo groups, respectively, at day 28; $p=0.67$) (Adlbrecht et al., 2020). The authors suggest that prevention of *P. aeruginosa* infection with a vaccine at the time of ICU admission may be too late. Indeed, in general, the humoral immune response is obtained about 2 to 3 weeks after the primary injection of the vaccine, which does not allow time to obtain a significant effect. Moreover, efficacy of the humoral response could be affected in some bacterial infections that are not systemic. An impact on mortality is also very difficult to demonstrate in critically ill patients, so another primary endpoint such as *P. aeruginosa*-related events would have been a better option. Nevertheless, this study demonstrated the feasibility of vaccinating a large cohort of ventilated patients in ICU and inducing a specific immune response (Adlbrecht et al., 2020).

Based on the literature search (Sainz-Mejías et al., 2020; Rello et al., 2017; Adlbrecht et al., 2020; Merakou et al., 2018; Bianconi et al., 2019), consultation of the clinical trials registry (ClinicalTrials.gov., 2021), and probably due to the recommendation published in the Cochrane Database of Systematic Reviews (Johansen and Gøtzsche, 2015), no vaccine is currently in clinical development (**Figure 4A**). An effective vaccine should be able to induce an humoral immune response capable of both mediating opsonophagocytic killing by phagocytic cells and neutralizing *P. aeruginosa* virulence factors (Sainz-Mejías et al., 2020). Advances have been made in understanding the interaction between *P. aeruginosa* and its host and the key role of Th1 and Th17 host immune responses are well established and a cellular immune response mediated by Th17 cells (Sainz-Mejías et al., 2020). A deeper understanding of these mechanisms at each potential site and stage of infection would facilitate future vaccine development. A novel approach such as reverse vaccinology combined with genomic technologies has recently been described in *P. aeruginosa*, identifying potentially surface-exposed immunogenic proteins relevant in pathogenesis (Bianconi et al., 2019). The use of outer membrane vesicles, because carrying many surface antigens which can serve as targets, also represent a promising approach for vaccine development (Antonelli et al., 2021).

ANTIBODIES: AN IMMEDIATE PASSIVE IMMUNIZATION TO TREAT OR PREVENT INFECTION

The vaccination (or active immunotherapy) strategy has various limitations, particularly for immunocompromised patients who may not be able to induce an appropriate immune response. Moreover, the immediate need for protection may not be met, including the time required for the development of an adequate immune response after vaccination, as discussed above (Adlbrecht et al., 2020). The uncommon mucus produced in the CF-lung can also be a barrier to the systemic and specific immune response against *P. aeruginosa* that colonize the lower airways. Nevertheless, antibodies represent an effective and specific line of defense of the immune system. Passive immunotherapy with antibacterial monoclonal antibodies (mAbs) is therefore an alternative therapy against *P. aeruginosa* that could be interesting in certain clinical situations. Indeed, mAbs target specific surface antigens that are not usually the targets of antibiotics and are thus active against MDR bacteria. Antibacterial strategies are developed by mAbs binding to bacterial surface antigens, inducing opsonophagocytic killing by the host immune system or by binding to a virulence factor, such as toxin, and thus neutralizing it (Lakemeyer et al. 2018). To date, no mAbs against *P. aeruginosa* have been approved.

Among the latest anti-*P. aeruginosa* mAbs, AR101 and AR105 have been developed as adjuvant strategy to antibiotics. While AR101 targets the LPS serotype O11 surface O-antigen, AR105 targets

alginate, a polysaccharide required for biofilm formation (Zurawski et al., 2020; Lu et al., 2011). A phase IIa trial evaluating AR101 was completed in 2009 for hospital acquired pneumonia, showing promising results in clinical cure and survival rates (NCT00851435). A phase II trial testing the efficacy, safety and pharmacokinetic of AR105 in addition to standard-of-care (SOC) antibiotics for pneumonia caused by *P. aeruginosa* was started in 2017 (NCT03027609). MEDI3902, a bispecific mAb, is able to recognize two different targets of *P. aeruginosa*, each containing a distinct epitope: the T3SS needle-tip protein PcrV, involved in host cell cytotoxicity and the surface exopolysaccharide Psl, involved in epithelial attachment and biofilm formation (**Figure 2**; Sato et al., 2011; Ryder et al., 2007). Designated as a Fast track drug from Food and Drug Administration (FDA), MEDI3902 is under development for the prevention of healthcare-acquired *P. aeruginosa* pneumonia in high-risk patients¹. PsAer-IgY (egg yolk immunoglobulin), an avian polyclonal anti-*P. aeruginosa* antibody, has entered in a phase III trial to test its efficacy in preventing recurrence of *P. aeruginosa* infection in CF patients (Thomsen et al., 2016).

But what's new in the clinical development pipeline since the 2017 WHO alert?

Currently in clinical development in China, the future of AR101 is unclear. Being specific to just one set of *P. aeruginosa* strains, AR101 mAbs may have limited value in contrast to MEDI3902 directed against independent and highly conserved target serotypes among clinical isolates (Tabor et al., 2018). In 2019, the developers reported that AR105 was unable to demonstrate superiority over SOC for clinical cure of *P. aeruginosa* pneumonia in phase II trial²; no further development resources were allocated to AR-105. In 2018, several years after the completion of the phase II study in CF patients infected with *P. aeruginosa*, results of KB001A were finally published (VanDevanter and Chmiel., 2018). KB001A is a monospecific PEGylated anti-PcrV mAb. Because no statistical difference was observed in time to antibiotic use compared to placebo, the primary endpoint was unfortunately not met. According to the authors, the low levels of T3SS secretion activity of *P. aeruginosa* isolates from CF patients may be an explanation for the lack of efficacy observed with KB001A in this study (VanDevanter and Chmiel., 2018).

Early use in healthier patients may be effective in reducing the inflammatory effect responsible for lung disease progression (VanDevanter and Chmiel., 2018). Published in 2019, results from the phase I study of MEDI3902 in healthy subjects (Ali et al., 2019), supported further evaluation in phase II proof-of-concept study in mechanically ventilated ICU patients at high risk for *P. aeruginosa* pneumonia. Even when bi-specific, MEDI3902 did not achieve the primary efficacy endpoint of reducing *P. aeruginosa* pneumonia (Chastre et al., 2020). Nevertheless, positive exploratory results were observed in subjects with lower levels of baseline inflammatory biomarkers, a subpopulation that could be tested to benefit from MEDI3902 (Chastre et al., 2020). While PsAer-IgY was safe in the population studied, efficacy could not be demonstrated with the trial design used, as stated in the final report (EU Clinical Trial register, 2018). The time to first recurrence of *P. aeruginosa* in patient sputum was not significantly different between active treatment and placebo. One explanation for this result could be that the non-specific IgY used as a comparator is also effective in postponing infection but in a nonspecific way (EU Clinical Trial register, 2018). The low efficacy could also be due to use antibodies from another species in humans responsible of neutralizing anti-IgY antibodies production. TRL1068, a human mAb targeting DNA Binding protein II (DNABII) is a promising new agent in

¹AstraZeneca website: <https://www.astrazeneca.com/media-centre/press-releases/2014/medimmune-fda-medi3902-nosocomial-pneumonia-prevention-23092014.html#modal-historic-confirmation> [Accessed December 2021]

²Aridis Pharmaceuticals website: <https://investors.aridispharma.com/2019-09-03-Aridis-Pharmaceuticals-Reports-Phase-2-Clinical-Trial-Results-of-AR-105-for-the-Treatment-of-Ventilator-Associated-Pneumonia-Caused-by-Pseudomonas-Aeruginosa> [Accessed December 2021]

³Trellis bioscience website: www.trellisbio.com/pipeline/bacteria.html [Accessed December 2021]

the antibody potentially effective against biofilm produced by a wide range of clinically relevant pathogens, including 10 of the 12 WHO priority pathogens³. Nevertheless, this efficacy could be low with early isolates that does not produce biofilm or are lower producers.

POLYMYXIN DERIVATIVES: A NEW “OLD” CLASS OF ANTIBIOTICS

Almost 60 years after their clinical approval, polymyxins remain a class of antibiotic available for many MDR Gram-negative bacteria, but used as last line therapeutic option due to their potential human nephro- and neurotoxicity (Li et al., 2019). Polymyxins are small cyclic cationic lipopeptides, interacting with the anionic lipid A component of LPS, in the outer membrane of Gram-negative bacteria, leading to cytoplasmic membrane disruption and bacterial cytotoxicity (Li et al., 2019). Their clinical use has restarted in recent years with polymyxin B and polymyxin E (colistin). Based on structure-activity-toxicity relationships, many efforts have been made to modify the original polymyxins and improve their safety profile. SPR741 is a polymyxin B derivative with less nephrotoxicity. SPR741 has no direct antibacterial activity but potentiates the efficacy of co-administered antibiotics (French et al., 2020), which alone would not have access to their intracellular targets (Corbett et al., 2017). SPR741 completed a phase I clinical trial in 2017 (Eckburg et al., 2019).

But what’s new in the clinical development pipeline since the 2017 WHO alert?

SPR741, combined with 3 different wide spectrum β -lactam antibiotics (ceftazidime, piperacillin/tazobactam, and aztreonam), showed favorable tolerability and PK profiles in a phase Ib study (Eckburg et al., 2019). The most effective combinations of such a “potentiator” strategy are not known yet, especially in non-healthy patient (Theuretzbacher et al., 2020). The clinical program for SPR741 have been halted by the developers in 2020 before phase II in favor of the potentially more promising SPR206 molecule (WHO, 2021). This kind of strategic choice is also a reality of clinical development, explaining the dynamic change in the pipeline of molecules. SPR206 is another polymyxin B derivative, designed for use alone, and has shown antibiotic activity against MDR Gram-negative pathogens and XDR bacterial strains, including CRPA, in preclinical studies. It has thus a potential broad-spectrum of activity (Brown et al., 2019). Data from a phase I clinical trial were recently published with no evidence of nephrotoxicity and supporting further development of SPR206 (Bruss et al., 2021). Two additional Phase I trials (**Figure 4B**) were also completed in December 2021: a bronchoalveolar lavage clinical trial assessing SPR206 penetration into the lungs, and a renal failure study. How polymyxin resistance and cross-resistance to other classes might develop over time is not known. The benefit of SPR206 on polymyxin-resistant strains must be demonstrated and lower toxicity must be shown in patients (Theuretzbacher et al., 2020). Nevertheless, the FDA has granted SPR206 Qualified Infectious Disease Product (QIDP) designation for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP) (Bruss et al., 2021), making this drug eligible for fast-track evaluation. MRX8, another polymyxin B derivative, started its clinical development on November 2020 (NCT04649541). MRX-8 was developed using a “soft drug design” which represents a new approach to designing safer drugs by integrating metabolism and detoxification factors into the drug design process (Lepak et al., 2020).

ANTIBIOTICS WITH A NEW MODE OF ACTION FOR MDR GRAM-NEGATIVE BACTERIA

Among bacterial targets, peptidoglycan (PG) synthesis remains a privileged target with investigations on molecules of the β -lactams family. One field of development focuses on the modification active β -lactams by addition of an iron-chelating molecule, facilitating transport into bacteria (De Carvalho and Fernandes, 2014). Cefiderocol, a first in class of siderophore-cephalosporins, is able to bind to

extracellular free iron, allowing active transport into the periplasmic space of Gram-negative bacteria through siderophore uptake systems. Cefiderocol subsequently binds to penicillin binding proteins (PBPs), inhibiting bacterial PG cell wall synthesis which leads to cell lysis and death (EMA, 2020). Although siderophore-antibiotics have been investigated for several decades, none of them progressed to clinical development because of poor correlation between *in vitro* activity and *in vivo* efficacy or because of toxicity (El-Lababidi. and Rizk, 2020). Promising assessment of cefiderocol for the treatment of cUTI in patients at risk of MDR Gram-negative infections started in phase II trial in 2015 (Portsmouth et al., 2018).

Lipopolysaccharide (LPS) that constitutes the OM outer layer at the surface of Gram-negative bacteria represents also an attractive target against pathogens (MacNair et al., 2020). By binding to the LPS transport protein D (LptD), the small cyclic peptide murepavadin causes a specific *P. aeruginosa* LPS biogenesis alteration (Martin-Loeches et al., 2018). A second phase II study of murepavadin co-administered with SOC in VAP due to *P. aeruginosa* finished in 2017 (NCT02096328).

But what's new in the development pipeline since the 2017 WHO alert?

In 2018, phase II results of cefiderocol versus imipenem-cilastatin, an available therapy for the treatment of cUTI were published. Response rates for the composite endpoint of microbiological eradication and clinical response were significantly higher in the cefiderocol arm compared with imipenem-cilastatin arm establishing the non-inferiority of cefiderocol (Portsmouth et al., 2018). The safety profile of cefiderocol in this study was good. On the basis of these results, cefiderocol was given priority review and was the first siderophore-antibiotic approved by the FDA in 2019¹, providing a new option of treatment of cUTI including pyelonephritis in patient with limited or no alternative treatment (FDA, 2019). Evaluated as non-inferior to meropenem for the primary endpoint of all-cause mortality in a phase III trial, cefiderocol has obtained an expanded indication for HAP and VAP (FDA, 2020; Wunderink et al., 2021). However, an increase in all-cause mortality death and infection-related death with treatment failure was observed in patients treated with cefiderocol compared with best available therapy in a descriptive phase III trial in critically ill patients with Gram-negative CR bacterial infections (Bassetti et al, 2021). The cause of the increase in mortality has not been established but close monitoring of the clinical response to therapy in patients with cUTI and HAP/VAP was asking by FDA (FDA, 2020). In 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization in Europe. The overall nonclinical and clinical data support the ability of cefiderocol to address an unmet need. The balance of benefits and risks is considered positive (EMA, 2020).

Murepavadin fulfilled innovation criteria (WHO 2019), including the main criteria for absence of known cross-resistance (Burrows, 2018), and reached phase III trials in HAP/VAP caused by *P. aeruginosa* (NCT03582007, NCT03409679). Unfortunately, murepavadin was prematurely withdrawn from the authorization race on July 2019 due to high incidence of kidney injury², another hard reality of clinical development that can be interrupted even in late phase due to imbalance of benefit/risk ratio for patients. An alternative mode of administration of murepavadin, such as inhalation, is being explored to improve nephrotoxicity. A new phase I has been announced to start in 2022³. In 2019, RC01 another new antibiotic targeting LPS biogenesis entered in clinical development (**Figure 4B**). RC01 inhibits the bacterial enzyme LpxC, a key protein involved in the production of LPS lipid A. Despite demonstrated efficacy in clinical isolates of *P. aeruginosa* from CF patients and good safety in preclinical phases, the phase I prematurely stopped for safety concerns (NCT03832517). As

¹FDA News Release December 16, 2019. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts> [Accessed December 2021]

²Polyphor website: <https://www.polyphor.com/news/corporate-news-details/?newsid=1800485> [Accessed December 2021]

³Polyphor website: <https://www.polyphor.com/news-adhoc/news-detail/?newsid=2176875> [Accessed December 2021]

309 NEW COMBINATIONS OF β -LACTAM/ β -LACTAMASE INHIBITOR: A STRATEGY TO 310 GET AROUND RESISTANCE

311 Among antibiotics, β -Lactam targets specifically the PG biosynthesis through covalent
312 binding/interaction to PBPs, the enzyme involved in late stages of PG synthesis. However, bacteria
313 under selection pressure could produce β -lactamases, enzymes who hydrolyzed the β -Lactam ring.
314 Hydrolyzing β -lactam antibiotics has made many of them ineffective becoming a major resistance issue
315 in Gram-negative bacteria (Tümmler, 2019). Consequently, a synergic combination of β -lactam and an
316 appropriate β -lactamase inhibitor (BLI) restoring β -lactam activity is a frequently used strategy. The
317 well-known combination amoxicillin (β -lactam)/clavulanic acid (BLI) is a good example as it
318 represents one of the most prescribed antibiotic worldwide and is a WHO-designed “core access
319 antibiotic” that should be consistently available (Sharland et al., 2018).

320 Relebactam is a new BLI with activity against a broad range of β -lactamase enzymes including
321 carbapenemases (Smith et al. 2020). *In vitro* addition of relebactam to imipenem restored imipenem
322 activity against several imipenem-resistant bacteria, including *P. aeruginosa* (Smith et al. 2020).
323 Relebactam in association with imipenem-cilastatin demonstrated efficacy in phase II trials dedicated
324 to complicated urinary tract infections (cUTIs) (Sims et al., 2017) and complicated intraabdominal
325 infections (cIAIs) (Lucasti et al., 2016), thus entered in phase III trial in HAP/VAP (Titov et al., 2020)
326 *versus* piperacillin-tazobactam and imipenem-resistant pathogens *versus* colistin (Motsch et al., 2020),
327 a polymixin used as last resort therapy. Taniborbactam is a highly potent pan-spectrum new BLI that
328 inhibits all classes of β -lactamase enzymes (Liu et al., 2020). In combination with the fourth-generation
329 cephalosporin cefepime, taniborbactam positively completed the phase I milestone in 2017 and thus
330 supported other trials (Dowell et al., 2020).

331 But what’s new in the clinical development pipeline since the 2017 WHO alert

332 Evaluation of phases II/III clinical data (Sims et al., 2017; Lucasti et al., 2016; Titov et al., 2020;
333 Motsch et al., 2020) demonstrates that the relebactam/imipenem-cilastatin association is well tolerated
334 and effective in the treatment of cUTIs, cIAIs, HAP/VAP and obtained FDA approval for these
335 therapeutic indications^{1,2}. Taniborbactam/cefepime association demonstrated *in vitro* rescue of
336 cefepime activity by taniborbactam against clinical isolates of CRPA (Hamrick et al., 2020). Fast Track
337 designated by the FDA, the association skipped phase II and is currently on phase III trial to access the
338 safety and efficacy compared with meropenem in both eradication of bacteria and in symptomatic
339 response as primary endpoint in patients with cUTIs including acute pyelonephritis (NCT03840148).
340 Another phase III trial in patients with HAP/VAP is scheduled to begin in 2022³. At least four other
341 new BLI in association with β -lactam are on phase I stage (completed or ongoing) (**Figure 4C**):
342 nacubactam, zidebactam, QPX7728 and XNW4107. Whereas nacubactam reported narrow *in vitro*
343 activity in *P. aeruginosa* (Asempa et al., 2020), QPX7728 is an ultra-broad-spectrum β -lactamase
344 inhibitor with the broadest spectrum of inhibition *in vitro* reported to date in a single BLI molecule
345 (Lomovskaya et al. 2020). Zidebactam in association with cefepime should start a phase III in cUTI or
346 acute pyelonephritis end of 2021 (NCT04979806). Despite this antibiotic-based strategy, other
347 mechanisms can unfortunately confer resistance to β -lactam/BLI new combinations. Beyond β -
348 lactamases production, overproduction or extended-spectrum β -lactamases, *P. aeruginosa* has
349 developed efficient mechanisms as decreased permeability of the outer membrane and overproduction
350 of efflux pumps (Moradali et al., 2017).

¹FDA website: [FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections](#) | FDA [accessed December 2021]

²FDA website: [FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia](#) | FDA [Accessed December 2021]

³Venatorx website: <https://www.venatorx.com/press-releases/venatorx-pharmaceuticals-provides-update-on-cefepime-taniborbactam/> [Accessed December 2021]

Bacteriophages that infect and lyse their target bacteria are being reconsidered as an alternative therapy to treat MDR bacterial infections. Interestingly, some phages are also able to disrupt biofilm barrier with EPS-depolymerase activity (Cornelissen et al., 2012). Phage therapy includes mono-phage, phages-cocktail, phage-derived enzyme (lysin), bio-engineered phage and phage combined with antibiotics (Patil et al., 2021). Systematic literature search shows a large number of case study reports and compassionate use for severe patients in specialized centers but despite promising results recent clinical trial evidence-based will be necessary. The first randomized controlled trial using a cocktail of natural lytic *P. aeruginosa* phages for the topical treatment of infected burn wound patients, was stopped on January 2017 because of PP1131 insufficient efficacy versus SOC (Jault et al., 2019).

But what's new in the clinical development pipeline since the 2017 WHO alert?

In 2019, full results of the phase I/II trial testing PP1131 were published. This study had several limitations and encountered many unexpected difficulties. An ancillary analysis showed that the bacteria isolated from patients with failed PP1131 treatment were resistant to low phage doses (Jault et al., 2019). Phage cocktails of predefined composition could negatively interfere in the relations between phage and bacterium by selecting phage resistance in the bacterial populations that vary among patients (Tümmler, 2019). An individually approach could be a more effective using phagograms to study *in vitro* the sensitivity of *P. aeruginosa* to bacteriophages in the manner of antibiograms, and a phage collection for personalized treatment (Friman et al., 2016).

APPA02¹, a new inhaled cocktail of complementary phages, is currently tested for safety and tolerability in a phase I/II trial to treat serious respiratory infections, with an initial emphasis on CF patients (NCT04596319). *P. aeruginosa* recovery in sputum following multiple doses of treatment will be also explored. In March 2021, a phase I/II trial was initiated for assessment of another targeted inhaled phage therapy YPT01² added to standard antimicrobial therapy in the treatment of chronic *P. aeruginosa* infections in CF (NCT04684641). A multispecies targeting topic phage cocktail TP102³ was formulated against *P. aeruginosa* but also *Staphylococcus aureus* and *Acinetobacter baumannii*. TP102 started a safety evaluation in subjects with both non-infected and infected diabetic foot ulcers as the primary endpoint and targeted bacteria clearance as secondary endpoint (NCT04803708). Results of these 3 early phase studies for APPA02, YPT01 and TP102 assessment are expected in 2022. BX004-A, a nebulized bacteriophage therapy entered in a phase Ia/IIb (Figure 4D). Exploratory objectives include whether this treatment reduces sputum *P. aeruginosa* bacterial load in CF subjects with chronic *P. aeruginosa* pulmonary infection (NCT05010577). During the same time, other new topical phage therapies by spray as an adjunct to SOC therapy for the prevention and treatment of *P. aeruginosa*, *S. aureus*, or *Klebsiella pneumoniae* infections will enter in development in pressure ulcers (PL03BM, NCT04815798) and burns (PGX0100, NCT04323475). Despite promising results, both historically and recently, the efficacy of phage therapy has still not been sufficiently examined and documented in high-quality clinical trial in humans to answer the questions raised about how to best use bacteriophages (Leitner et al., 2021).

DEPRIVING BACTERIA FROM A SURVIVAL ESSENTIAL ELEMENT: IRON

As an essential nutrient for growth and biofilm establishment, *P. aeruginosa* has developed different

¹Armata Pharmaceutical website : <https://www.armatapharma.com/pipeline/ap-pa02/> [Accessed December 2021]

²Felix Biotechnology website : <https://www.felixbt.com/new-page> [Accessed December 2021]

³Technophage website: <http://technophage.pt/pipeline/> [Accessed December 2021]

2021). Acting as an iron mimetic, gallium disrupts multiple iron-dependent synthetic and metabolic

pathways (Frei, 2020). Preliminary clinical study raised the possibility that gallium may be a safe and effective treatment for human infections (Goss et al., 2018). A phase II study to test IV gallium nitrate to control *P. aeruginosa* infections in adults with CF started in 2016 (NCT02354859). Because the IV form of gallium involves a continuous 5-days infusion, which is a demanding treatment regimen for patients, the AR501 inhaled formulation of gallium citrate self-administered via a nebulizer device was designed to be given once a week, allowing for direct delivery to the lungs¹. Another antimicrobial with an activity on iron metabolism is ALX-009, a combination of lactoferrin and hypothiocyanite, natural major antimicrobial substances deficient in the airway secretions of CF patients (Tunney et al., 2018). Lactoferrin deprive bacteria of iron due to its iron chelator activity and can bind to cell membranes leading to alterations in permeability and enhancing bacterial killing by other antibiotics (Rogan et al., 2004). Hypothiocyanite is a highly reactive compound that oxidizes proteins to create disulfide bonds that perturb the bacterial physiology (Thomas et al., 1978). ALX009 started a phase I in 2015 as an inhalable solution administered through nebulization (NCT02598999).

But what's new in the clinical development pipeline since the 2017 WHO alert?

The phase II clinical trial in adults with CF found no significant difference between the number of responders (defined as a participant having a 5% or greater increase in lung function by day 28) in the IV gallium nitrate and placebo group¹. The primary endpoint was unmet, however a significant reduction of *P. aeruginosa* was found in the sputum of gallium treated patients compared to the placebo group for participants who were culture positive for *P. aeruginosa* at baseline². Overall, IV gallium nitrate was well-tolerated compared to placebo. With broad-spectrum anti-infective activity AR501 is being developed in a phase I/IIa (**Figure 4D**) to treat chronic bacterial lung infections of CF patients (NCT03669614). On 2020 positive safety data were reported from the phase I portion of the study, and AR-501 has been granted Fast Track, Qualified Infectious Disease Product, and Orphan Drug Designation by FDA and EMA. The originally planned protocol design was adapted into a phase IIa (dose selection / sample size determination) which results expected in 2022 will be implemented directly in a phase IIb study (efficacy) using the same clinical study protocol³. This is an encouraging example of simplified and accelerated development supported by Health Authorities in a context of urgent need. Final data collection date for primary outcome measure of ALX009 in healthy volunteers and patients suffering from CF and non-CF bronchiectasis was expected in October 2021 (NCT02598999).

ANTI-BIOFILM STRATEGY

Among virulence factors of *P. aeruginosa*, biofilms increase bacterial adherence, immune system evasion and antibiotic tolerance by blocking the diffusion of positively charged drugs. OligoG is an alginate oligosaccharide with the potential to reduce sputum viscosity of CF patients by chelating calcium (Ermund et al., 2017), easing clearance of mucus from patient airways, reducing microbial burden and inflammation. OligoG was also shown to disrupt biofilm structure of *P. aeruginosa* mucoid phenotype (Powell et al., 2018) and could in consequence improve host immune system action and the effectiveness of antimicrobial agents. To determine the safety and local tolerability of multiple dose administration of inhaled fragment in healthy volunteers, a phase I study was performed with a particular attention on pulmonary functioning and adverse events (NCT00970346).

¹Aridis pharmaceutical website : <https://www.aridispharma.com/ar-501/> [Accessed December 2021]

²Cystic Fibrosis Foundation website : <https://www.cff.org/Trials/Finder/details/374/IGNITE-Safety-and-effectiveness-of-gallium-nitrate-in-adults-with-cystic-fibrosis> [Accessed December 2021]

³Aridis Pharmaceuticals website: [Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501 - Sep 8, 2020 \(aridispharma.com\)](https://www.aridispharma.com/press-releases/aridis-announces-agreement-with-the-fda-on-updated-phase-2-clinical-trial-design-for-ar-501-sep-8-2020) [Accessed December 2021]

FEV₁ (forced expiratory volume by the patient in one second) was not reached^{1,2,3}. Lung function is

widely used as primary outcome measure in the development of drugs to treat CF but regarding its mode of action could not be adapted to prove an OligoG efficacy, especially when disease is already installed. *Post hoc* subgroup analyses support mechanism of action for OligoG and warrant further prospective studies (Van Koningsbruggen-Rietschel et al., 2020). OligoG has Orphan Drug designation from both the EMA and the FDA and is currently tested in other phase IIb studies in addition to SOC compared to placebo with SOC too (NCT03698448 and NCT03822455). SNSP113 (SYGN113), a novel large polycationic glycopolymer, poly (acetyl, arginyl) glucosamine was tested in a phase I study in healthy subjects and patients with stable CF (NCT03309358) and is currently evaluated in a phase II study (**Figure 4E**). PLG0206 (WLB02), an engineered cationic antimicrobial peptide with broad-spectrum activity and preventing *in vitro* *P. aeruginosa* biofilm growth on airway epithelial cells (Lashua et al., 2016), received Orphan Drug status for prosthetic joint infection and entered in phase 1 trial in healthy subjects in 2018. PLG0206 will enter a phase 1b for treatment of periprosthetic joint infection in 2022 (NCT05137314).

OTHER INNOVATIVE ANTI-VIRULENCE STRATEGIES

As T3SS and associated toxins are major virulence factors of *P. aeruginosa* (**Figure 2**), innovative therapeutic strategies are developed to reduce the infection severity. Despite many hopes based on *in vitro* or preclinical activities, only one treatment targeting T3SS is currently in clinical development (**Figure 4E**). Ftortiazinon, a small molecule with a strong potential as an antibacterial therapy (Sheremet et al., 2020), developed by the Gamaleya Research Institute, entered a phase 2 in combination with cefepime for the treatment of patients with cUTI caused by *P. aeruginosa* in 2018 (NCT03638830).

DISCUSSION

This review aimed at providing an up-to-date picture of therapeutics against *P. aeruginosa* currently in clinical development, since the 2017 WHO alert. Only one antibacterial drug with a new mode of action has been approved by FDA and EMA against *P. aeruginosa* (**Figure 4B**). Among 18 drugs of interest anti-*P. aeruginosa* in the development pipeline described in this review, only one new combination of β -lactam/ β -lactamase inhibitor of antibiotics is in phase III trial (**Figure 4C**). Derivatives of existing antibiotics considered as “traditional agents” are highly represented (**Figure 5**). Diverse “non-traditional agents” including bacteriophages, iron mimetic/chelator and anti-virulence factors are significantly represented but unfortunately still in early clinical stages. There is no vaccine in development to prevent *P. aeruginosa* infections despite a half century of research effort specifically focused on this challenge (Sainz-Mejías et al., 2020; ClinicalTrials.gov., 2021).

Studying pipeline anti-*P. aeruginosa* since 2017 up to now, shows how development of a new treatment can be a difficult process. Lack of correspondence between *in vitro* or preclinical study and phase II clinical response questions the choice of pertinent animal models recreating human infection conditions (Theuretzbacher et al., 2019; Theuretzbacher et al., 2020). Methodology used is often a strategic issue, with the crucial definition of the clinically significant primary outcome (Adlbrecht et al., 2020; Merakou et al., 2018) and the infection-site that could best allow to meet efficacy criteria. The absence of statistically significative evidence is not the evidence of absence of efficacy. We can question for example if death is a good primary outcome when critically ill patients are entering in ICU (Merakou et al., 2018) and if lung function measure is a pertinent primary outcome for a CF patient with chronical severe disease (Ali et al., 2019; Van Koningsbruggen-Rietschel et al., 2020). Studying pipeline also underlines that a late clinical stage development can be interrupted due to unexpected

toxicity¹ or bankrupt of a biotechnology company. COVID-19 pandemic had also an important impact on clinical trials recruitment and timelines during the last 2 years.

P. aeruginosa–host interactions and host immunometabolism are not yet enough understood, complicating the development of effective therapies and vaccines (Sainz-Mejías et al., 2020). Due to the fact that *P. aeruginosa* is an opportunistic bacterium, patients infected with *P. aeruginosa* are mostly immunocompromised individuals. This make it difficult to develop a vaccine for these patients (Yaeger et al., 2021). As *P. aeruginosa* is characterized by its genomic plasticity, drugs or vaccine must be designed to target conserved elements between strains to ensure an optimal efficacy (Tse et al., 2017). This constitutes a true limitation regarding strains like PA7, a non-respiratory MDR that lacks the T3SS and its effectors or the exotoxin A (Roy et al., 2010) or the Liverpool epidemic strain, a lineage with enhanced virulence and antimicrobial resistance characteristics (Salunkhe et al., 2005).

Each class of treatment against *P. aeruginosa* presents strengths, weaknesses, opportunities and threatens that have to be taken into account in global clinical development considerations (**Figure 6**). Among “non-traditional agents”, a vaccine could offer a long-term sustainable approach to infection prevention because it will decrease the need for antibiotics and hence the emergence of antibioresistance (Micoli et al., 2021). Anti-virulence strategy may have the potential through novel, specialized and non-killing modes of action to reduce the selective pressure responsible of MDR (Dickey et al., 2017) or select less virulent strains. Regarding combinatory multifactorial virulence, an anti-virulence factor used alone do not has therapeutic utility and hence must be used as pre-emptive or adjunctive treatment in combination with traditional antibiotics (Dickey et al., 2017). Despite many years of research, no anti-virulent agent has yet been introduced in clinical use against *P. aeruginosa*. Novel targets for anti-virulence strategy must be proposed and T6SS as a key virulence factor of *P. aeruginosa* (**Figure 2**) could be selected. Inhibition of T6SS assembly or neutralization of its toxins (amidases, phospholipases, protease, pore forming toxin and iron-acquisition effector) (**Figure 2**) would allow to interfere at two moments of the infectious process: (i) during host colonization (competition for the niche with microbiota or other pathogens in case of CF patients) and (ii) escape from the immune system (internalization and autophagy).

Current antibiotics are less effective due to increasing resistance and some *P. aeruginosa* isolates are resistant to all available treatments, underlying the unmet medical need. Given the development duration, the pipeline remains unsatisfactory leading best case to the approval of new antibacterial drugs that treat CRPA in several years. And as the United Nations, WHO and numerous experts published in an April 29, 2019, report, immediate, coordinated and ambitious action must be taken to avoid a potentially disastrous antimicrobial resistance crisis. If not, drug-resistant diseases could cause 10 million deaths each year by 2050 warns the UN Inter-Agency Coordination Task Force on Antimicrobial Resistance¹. Developing a new treatment takes years, however COVID-19 pandemic has demonstrated that it is possible to accelerate the development of a molecule or a vaccine in case of crisis (Krammer, 2020). Beyond the investments needed to build a robust pipeline, the Community need to reinvent medicine with new strategies of development to avoid the disaster.

ACKNOWLEDGEMENTS

We thank members of SB team for support. Work of S.B. team is funded by the Centre National de la Recherche Scientifique, the Aix-Marseille Université, and by grant from the Agence Nationale de la Recherche (ANR-21-CE11-0028-01). A.L.G. is supported by “Vaincre la mucoviscidose” (VLM) and “Association Grégory Lemarchal” (Grant number RF20190502416 and RF20210502854), ANR-15-IDEX-02, SATT Linksum and Fondation Université Grenoble Alpes.

¹WHO website news release on 29 April 2019: [New report calls for urgent action to avert antimicrobial resistance crisis \(who.int\)](https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis) [Accessed December 2021]

526 FIGURE LEGENDS

527 **FIGURE 1. Clinical manifestations of *P. aeruginosa* infections.** Representation of human body site
 528 infections and main clinical manifestations of *P. aeruginosa*. Healthcare-associated infections
 529 highlighted in blue illustrate the significant burden of *P. aeruginosa* on invasive acts, surgery, devices
 530 use resulting in local or systemic complications (Dando et al., 2014 ; Shrestha et al., 2021; Durand,
 531 2017; Arsovic et al., 2020; Ramireddy et al., 2020; Elborn, 2016; Chai and Xu, 2020; Shukla et al.,
 532 2020; Jean et al., 2020; Montravers et al., 2020; Wu et al., 2011; Gahlot et al., 2014, Newman et al.,
 533 2017; Cerioli et al., 2020; Vieira et al., 2016; Hauser and Ozer, 2011).

534 **FIGURE 2. Key virulence factors of *P. aeruginosa*.** Schematic representation of cell associated and
 535 extracellular relevant virulence factors and their main roles on *P. aeruginosa* pathogenesis. OMPs,
 536 outer membrane proteins; LPS, lipopolysaccharide; ROS, reactive oxygen species; EPS,
 537 exopolysaccharides; eDNA, extracellular desoxyribonucleic acid; T4P, type 4 pili; TnSS, type n
 538 secretion system; ETA, exotoxin A; PVD, pyoverdine; PCH, pyochelin; PCN; pyocyanin; PG,
 539 peptidoglycan; ECM, extracellular (Alhazmi, 2015; Jurado-Martín et al., 2021; Sana et al., 2016; Berni
 540 et al., 2019; Nolan et al., 2021).

541 **FIGURE 3. Review focus, data search criteria and strategy.**

542
 543 **FIGURE 4A. Search results: anti-*Pseudomonas aeruginosa* clinical development pipeline in**
 544 **December 2021.** MoA, mode of action; IM, intramuscular; IV, intravenous; Ig; immunoglobulin;
 545 mAb, monoclonal antibody; pAb, polyclonal antibody; eDNA, extracellular desoxyribonucleic acid.

546 **FIGURE 4B. Search results: anti-*Pseudomonas aeruginosa* clinical development pipeline in**
 547 **December 2021.** MoA, mode of action; IV, intravenous; PG, peptidoglycan; LPS,
 548 lipopolysaccharide.

549 **FIGURE 4C. Search results: anti-*Pseudomonas aeruginosa* clinical development pipeline in**
 550 **December 2021.** MoA, mode of action; IV, intravenous; PG, peptidoglycan.

551 **FIGURE 4D. Search results: anti-*Pseudomonas aeruginosa* clinical development pipeline in**
 552 **December 2021.** MoA, mode of action; IV, intravenous.

553 **FIGURE 4E. Search results: anti-*Pseudomonas aeruginosa* clinical development pipeline in**
 554 **December 2021.** MoA, mode of action; IV, intravenous; T3SS, type 3 secretion system.

555 **FIGURE 5. Anti-*Pseudomonas aeruginosa* treatments in clinical development in December**
 556 **2021.**

557 **TABLE 1. Strengths and weaknesses (internal factors), opportunities and threats (external**
 558 **factors) of each class of treatment in clinical development against *P. aeruginosa*.** This table is
 559 based on the following references for vaccines (Theuretzbacher et al., 2020; Micoli et al., 2021; Sainz-
 560 Mejías et al., 2020 ; Merakou et al., 2018 ; Bianconi et al., 2019 ; Antonelli et al., 2021), antibodies
 561 (Theuretzbacher et al., 2020 ; Yaeger et al., 2021; Adlbrecht et al., 2020 ; Lakemeyer et al., 2018;
 562 Zurawski et al., 2020), polymyxins (Li, et al., 2019; Theuretzbacher et al., 2020; Lepak et al., 2020),
 563 new antibiotics (WHO, 2021; Dickey et al., 2017; Tse et al., 2017), new combinations of β -lactam/ β -
 564 lactamase inhibitor (WHO, 2021 ; Theuretzbacher et al., 2020), phages (Patil et al., 2021; Jault et al.,
 565 2019; Friman et al., 2016), iron metabolism disruption (Zhang et al., 2021; Frei et al., 2020), anti-

566 biofilm (Dickey et al., 2017), other anti-virulence factors (Dickey et al., 2017, Theuretzbacher et al.,
567 2020).

Type	Strengths	Weaknesses	Opportunities	Threats
Vaccines	<ul style="list-style-type: none"> - Prophylactic strategy with a response in early stage of infection - Multitargeting possible/specificity - Reduced probability of resistance - Well define target population (high risks patients for opportunistic infection to improve immunity) 	<ul style="list-style-type: none"> - Non immediate action - Limited predictive value of animal models (immune system complexity) - Weak preclinical pipeline - No vaccine currently in clinical trial - Immunisation dependent of the patient immune system status 	<ul style="list-style-type: none"> - COVID-19 vaccine development change of paradigm - New technologies (reverse vaccinology, adjuvants optimization, mRNA) - Spread of MDR as a reason to consider vaccination 	<ul style="list-style-type: none"> - Image of low morbidity/mortality of <i>P. aeruginosa</i> infection in general population - Burden of disease and incidence rate not well define in high-risk patients - Development mostly in health-care associated pneumonia - Difficulties to generate robust data to support approval (how to design clinical trial regarding complexity of infections) - Non inferiority clinical trial (design strategy with lack of distinct benefit over existing treatment) - Non MDR arm used in the studies design; difficulties to recruit patients with MDR - Duration of clinical trial in the current development paradigm - High-risk strategies for innovative treatment (new targets or new type of drug; high attrition rate of phase I) - Cost of diagnosis before use of drugs with narrow spectrum - Cost of biotherapies manufacturing <i>versus</i> traditional drugs - Strong dependence on public and/or philanthropic funding - High need of innovation not or partially covered - Lack of commercial interest in developing new antibacterial drugs (high risk development, low return on investment expected, new drugs will be used as last resort) - Low economical value of novel antibiotic <i>versus</i> innovative treatment of chonical diseases - Many big pharmaceuticals companies abandoned R&D programs - Challenge of clinical development by biotechnologies companies
Antibodies	<ul style="list-style-type: none"> - Immediate protection (preventive or adjunctive therapy possible) - Immunisation independent of the patient immune system status - Multitargeting possible/specificity - Anti-virulence factors strategy with probability of reduced resistance - Narrow spectrum avoiding the disruption of microbiota 	<ul style="list-style-type: none"> - Mostly intravenous administration not ideal for immunocompromised patients - Large proteins - Usually narrow spectrum of activity necessitating diagnosis before to treat (specialized and costly health-care facilities) 	<ul style="list-style-type: none"> - mAb technology well know in cancer or autoimmune diseases treatment - Manufacturing methods and safety profile well established - DNAmAb to overcome cost 	
Polymyxins	<ul style="list-style-type: none"> - Broad-spectrum activity - Potentiate and extend the spectrum of conventional antibiotics (synergy) - Efficacy against both quiescent and growing bacteria 	<ul style="list-style-type: none"> - Emergence of resistance - Large spectrum of activity engendering dysbiose - Possible toxicity against host - Currently last line of defense 	<ul style="list-style-type: none"> - No newer alternatives : the urgent need to optimize their clinical use - Substantial progress made in understanding complexity of polymyxins and “soft drug design” 	
New antibiotics (new MoA)	<ul style="list-style-type: none"> - New mode of action less susceptible to induce resistance - Broad or narrow activity spectrum 	<ul style="list-style-type: none"> - Based on low evidence, clinicians appear reluctant to use new antibiotic agents - Safety profile less known 	<ul style="list-style-type: none"> - Substantial knowledges of rich ecological niches that produces antibiotics as secondary metabolite - Human microbiota research enthusiasm 	
New combinations of β-lactam/ β-lactamase inhibitor	<ul style="list-style-type: none"> - Synergic effect, restoring activity of β-lactam - Counteract β-lactamase defense strategy 	<ul style="list-style-type: none"> - Resistance mechanisms beyond the production of β-lactamases - Broad-spectrum of antibiotic resistance/cross resistance - Short term option 	<ul style="list-style-type: none"> - Highly developed antibacterial β-lactam based clinical pipeline. 	
Phages	<ul style="list-style-type: none"> - Self amplification at infection site - Biofilm penetration (possible lysis) - Specificity of action avoiding microbiome disruption - Escape mutants could be less pathogenic due to loss of surface factors expression 	<ul style="list-style-type: none"> - Lack of knowledge about phage mode of action - Strong selective pressure to develop resistance - Diagnosis necessary for personalized therapy - Immunogenicity of phage 	<ul style="list-style-type: none"> - Availability for patients in Eastern Europe specialized centers - Compasionate use as clinical experience - Cost effective - Human microbiome research (including largely phagome) 	
Iron metabolism disruption	<ul style="list-style-type: none"> - Activity against Gram-negative and Gram-positive (broad spectrum of activity) 	<ul style="list-style-type: none"> - Production of high level of siderophore pyoverdine to compensate - Lack of knowledges about exact mode of action 	<ul style="list-style-type: none"> - Untapped potential of metal-based antibiotics <i>versus</i> organics compounds 	
Anti-biofilm	<ul style="list-style-type: none"> - Sensibilize bacteria to antibiotic - Strategy with reduced probability of resistance - Can supplement antibiotics for increase efficacy - Specificity of action avoiding microbiota depletion 	<ul style="list-style-type: none"> - Requires a combination therapy - Effective in strain infection with mucoid phenotype 	<ul style="list-style-type: none"> - Substantial knowledges of virulence mechanisms of pathogen bacteria - Biofilm well recognized as a threat in healthcare institutions 	
Other anti-virulence factors	<ul style="list-style-type: none"> - Strategy with reduced probability of resistance or selection of less virulent strains - Specificity of action avoiding microbiota depletion 	<ul style="list-style-type: none"> - Diagnosis necessary for personalized therapy - Plasticity of virulence factors expression - Require a combination therapy 	<ul style="list-style-type: none"> - The rise of antivirulence strategy (large number of putative virulence targets) - Antivirulence drugs already approved (exotoxins blockage) 	

568

569 **CONFLICT OF INTEREST**

570 The authors declare that the research was conducted in the absence of any commercial or financial
 571 relationships that could be construed as a potential conflict of interest. S.R. is currently working in the
 572 Medical Department of Novartis Gene Therapies France SAS as Senior Medical Science Manager. S.
 573 R. is a PhD student independently of his professional position and on a totally different therapeutic
 574 area.

575 **AUTHORS CONTRIBUTIONS**

576 S. R., A. L. G. and S. B. wrote the manuscript.

577 **REFERENCES**

- 578 Adlbrecht, C., Wurm, R., Depuydt, P., Spapen, H., Lorente, J. A., Staudinger, T. et al. (2020). Efficacy,
 579 immunogenicity, and safety of IC43 recombinant *Pseudomonas aeruginosa* vaccine in mechanically
 580 ventilated intensive care patients-a randomized clinical trial. *Crit. Care.* 24(1):74. doi: 10.1186/s13054-
 581 020-2792-z.
- 582 Alhazmi, A. (2015). *Pseudomonas aeruginosa* – Pathogenesis and Pathogenic Mechanisms.
 583 *International Journal of Biology*; 7, 44-67. doi:10.5539/ijb.v7n2p44.
- 584 Ali, S. O., Yu, X. Q., Robbie, G. J., Wu, Y., Shoemaker, K., Yu, L, et al. (2019). Phase 1 study of
 585 MEDI3902, an investigational anti-*Pseudomonas aeruginosa* PcrV and Psl bispecific human
 586 monoclonal antibody, in healthy adults. *Clin. Microbiol. Infect.* 2019 May;25(5):629.e1-629.e6. doi:
 587 10.1016/j.cmi.2018.08.004.
- 588 Antonelli, G., Cappelli, L., Cinelli, P., Cuffaro, R., Manca, B., Nicchi, S. et al. (2021). Strategies to
 589 Tackle Antimicrobial Resistance: The Example of *Escherichia coli* and *Pseudomonas aeruginosa*. *Int.*
 590 *J. Mol. Sci.* 22(9):4943. doi: 10.3390/ijms22094943.
- 591 Arsovic, N., Radivojevic, N., Jesic, S., Babac, S., Cvorovic, L., Dudvarski, Z. (2020). Malignant Otitis
 592 Externa: Causes for Various Treatment Responses. *J. Int. Adv. Otol.* 16(1):98-103. doi:
 593 10.5152/iao.2020.7709.
- 594 Asempa, T. E., Motos, A., Abdelraouf, K., Bissantz, C., Zampaloni, C., Nicolau, D. P. (2020).
 595 Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing *Pseudomonas*
 596 *aeruginosa* in a neutropenic murine lung infection model. *Int. J. Antimicrob. Agents* 55(2):105838.
 597 doi: 10.1016/j.ijantimicag.2019.10.019.
- 598 Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y., Ferrer, R., et al. (2021). Efficacy and
 599 safety of cefiderocol or best available therapy for the treatment of serious infections caused by
 600 carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label,
 601 multicentre, pathogen-focused, descriptive, phase 3 trial. *Lancet Infect. Dis.* 21(2):226-240. doi:
 602 10.1016/S1473-3099(20)30796-9.
- 603 Berni, B., Soscia, C., Djermoun, S., Ize, B., Bleves, S. (2019). A Type VI Secretion System Trans-
 604 Kingdom Effector Is Required for the Delivery of a Novel Antibacterial Toxin in *Pseudomonas*
 605 *aeruginosa*. *Front. Microbiol.* 10:1218. doi: 10.3389/fmicb.2019.01218.

- 606 Bianconi, I., Alcalá-Franco, B., Scarselli, M., Dalsass, M., Buccato, S., Colaprico, A., Marchi, S.,
 607 Masignani, V., Bragonzi, A. (2019). Genome-Based Approach Delivers Vaccine Candidates
 608 Against *Pseudomonas aeruginosa*. *Front. Immunol.* 9:3021. doi: 10.3389/fimmu.2018.03021.
- 609 Brown, P., Abbott, E., Abdulle, O., Boakes, S., Coleman, S., Divall, N. et al. (2019). Design of Next
 610 Generation Polymyxins with Lower Toxicity: The Discovery of SPR206. *ACS Infect. Dis.* 5(10):1645-
 611 1656. doi: 10.1021/acsinfecdis.9b00217.
- 612 Bruss, J., Lister, T., Gupta, V. K., Stone, E., Morelli, L., Lei, Y. et al. (2021). Single- and Multiple-
 613 Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative
 614 SPR206. *Antimicrob. Agents Chemother.* 65(10):e0073921. doi: 10.1128/AAC.00739-21.
- 615 Burrows, L. L. (2018). The Therapeutic Pipeline for *Pseudomonas aeruginosa* Infections. *ACS Infect.*
 616 *Dis.* 4(7):1041-1047. doi: 10.1021/acsinfecdis.8b00112.
- 617 Cerioli, M., Batailler, C., Conrad, A., Roux, S., Perpoint, T., Becker, A., et al. (2020). *Pseudomonas*
 618 *aeruginosa* Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center
 619 in France. *Front. Med. (Lausanne)* 7:513242. doi: 10.3389/fmed.2020.513242.
- 620 Chai, Y. H. and Xu, J. F. (2020). How does *Pseudomonas aeruginosa* affect the progression of
 621 bronchiectasis? *Clin. Microbiol. Infect.* 26(3):313-318. doi: 10.1016/j.cmi.2019.07.010.
- 622 Chastre, J., François, B., Bourgeois, M., Komnos, A., Ferrer, R., Rahav, G. et al. (2020). Efficacy,
 623 Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-*Pseudomonas*
 624 *aeruginosa* Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit
 625 Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-
 626 MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program, *Open Forum Infectious*
 627 *Diseases* 7(Issue Supplement 1): 377–S378. doi: [10.1093/ofid/ofaa439.829](https://doi.org/10.1093/ofid/ofaa439.829)
- 628 Corbett, D., Wise, A., Langley, T., Skinne, K., Trimby, E., Birchall, S., Doral, A. et al. (2017).
 629 Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of
 630 SPR741. *Antimicrob. Agents Chemother.* 61(8):e00200-17. doi: 10.1128/AAC.00200-17.
- 631 Cornelissen, A., Ceyssens, P. J., Krylov, V. N., Noben, J. P., Volckaert, G., Lavigne, R. (2012).
 632 Identification of EPS-degrading activity within the tail spikes of the novel *Pseudomonas putida* phage
 633 AF. *Virology* 434(2):251-6. doi: 10.1016/j.virol.2012.09.030.
- 634 Dando, S. J., Mackay-Sim, A., Norton, R., Currie, B. J., St John, J. A., Ekberg, J. A et al. (2014).
 635 Pathogens penetrating the central nervous system: infection, pathways and the cellular and molecular
 636 mechanisms of invasion. *Clin. Microbiol. Rev.* 27(4):691-726. doi: 10.1128/CMR.00118-13.
- 637 De Carvalho, C. C. and Fernandes, P. (2014). Siderophores as "Trojan Horses": tackling multidrug
 638 resistance? *Front. Microbiol.* 5:290. doi: 10.3389/fmicb.2014.00290.
- 639 Dickey, S. W. and Cheung, G. Y. C. (2017). Otto M. Different drugs for bad bugs: antivirulence
 640 strategies in the age of antibiotic resistance. *Nat. Rev. Drug Discov.* 16(7):457-471. doi:
 641 10.1038/nrd.2017.23.
- 642 Dowell, J. A., Dickerson, D., Henkel, T. (2020). Safety and Pharmacokinetics in Human Volunteers of
 643 Taniborbactam (VNRX-5133), a Novel Intravenous β -Lactamase Inhibitor. *Antimicrob Agents*
 644 *Chemother.* 65(11):e0105321. doi: 10.1128/AAC.01053-21.
- 645 Durand, M. L. (2017). Bacterial and Fungal Endophthalmitis. *Clin. Microbiol. Rev.* 30(3):597-613.
 646 doi: 10.1128/CMR.00113-16.

- 647 Eckburg, P. B., Lister, T., Walpole, S., Keutzer, T., Utley, L., Tomayko, J. et al. (2019). Safety,
648 Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator,
649 after Single and Multiple Ascending Doses and When Combined with β -Lactam Antibiotics in Healthy
650 Subjects. *Antimicrob. Agents Chemother.* 63(9):e00892-19. doi: 10.1128/AAC.00892-19.
- 651 Elborn, J. S. (2016). Cystic fibrosis. *Lancet* 388(10059):2519-2531. doi: 10.1016/S0140-
652 6736(16)00576-6.
- 653 El-Lababidi, R. M. and Rizk, J. G. (2020). Cefiderocol: A Siderophore Cephalosporin. *Ann.*
654 *Pharmacother.* 54(12):1215-1231. doi: 10.1177/1060028020929988.
- 655 EMA, European Medicines Agency (2020). Fetcroja product information last updated 28/07/2020.
656 [http://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-](http://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf)
657 [information_en.pdf](http://www.ema.europa.eu/en/documents/product-information/fetcroja-epar-product-information_en.pdf)
- 658 EMA, European Medicines Agency (2020). 27 February 2020 EMA/CHMP/73102/2020 Committee
659 for Medicinal Products for Human Use. [https://www.ema.europa.eu/en/documents/smop-initial/chmp-](https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fetcroja_en.pdf)
660 [summary-positive-opinion-fetcroja_en.pdf](https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-fetcroja_en.pdf)
- 661 Ermund, A., Recktenwald, C. V., Skjåk-Braek, G., Meiss, L. N., Onsøyen, E., Rye, P. D. et al. (2017).
662 OligoG CF-5/20 normalizes cystic fibrosis mucus by chelating calcium. *Clin. Exp. Pharmacol. Physiol.*
663 2017 Jun;44(6):639-647. doi: 10.1111/1440-1681.12744.
- 664 EU Clinical Trial register (2018). Final study report. [https://www.clinicaltrialsregister.eu/ctr-](https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2011-000801-39/1/24990)
665 [search/rest/download/result/attachment/2011-000801-39/1/24990](https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2011-000801-39/1/24990)
- 666 FDA, US Food And Drug Administration (2019). Briefing Information for the October 16,
667 2019 Meeting of the Antimicrobial Drugs Advisory Committee.
668 <https://www.fda.gov/media/131703/download>
- 669 FDA, US Food And Drug Administration (2020). Highlights of prescribing information updated
670 09/2020. http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209445s002lbl.pdf
- 671 Frei, A. (2020). Metal Complexes, an Untapped Source of Antibiotic Potential? *Antibiotics* (Basel)
672 9(2):90. doi: 10.3390/antibiotics9020090.
- 673 French, S., Farha, M., Ellis, M. J., Sameer, Z., Côté, J. P., Cotroneo, N. et al. (2020). Potentiation of
674 Antibiotics against Gram-Negative Bacteria by Polymyxin B Analogue SPR741 from Unique
675 Perturbation of the Outer Membrane. *ACS Infect. Dis.* 2020 6(6):1405-1412. doi:
676 10.1021/acsinfecdis.9b00159.
- 677 Friman, V. P., Soanes-Brown, D., Sierocinski, P., Molin, S., Johansen, H. K., Merabishvili, M. et al.
678 (2016). Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered
679 resistance evolution with *Pseudomonas aeruginosa* cystic fibrosis bacterial isolates. *J. Evol. Biol.*
680 29(1):188-98. doi: 10.1111/jeb.12774.
- 681 Gahlot, R., Nigam, C., Kumar, V., Yadav, G., Anupurba, S. (2014). Catheter-related bloodstream
682 infections. *Int. J. Crit. Illn. Inj. Sci.* 4(2):162-7. doi: 10.4103/2229-5151.134184.
- 683 Gessard, C. (1882). De la pyocyanine et de son microbe ; colorations qui en dépendent dans les
684 liquides organiques. Applications cliniques. Medical Thesis.

- 685 Goss, C. H., Kaneko, Y., Khuu, L., Anderson, G. D., Ravishankar, S., Aitken, M. L. et al. (2018).
 686 Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung
 687 infections. *Sci. Transl. Med.* 10(460):eaat7520. doi: 10.3390/antibiotics9020090.
- 688 Hamrick, J. C., Docquier, J. D., Uehara, T., Myers, C. L., Six, D. A., Chatwin, C. L. et al. (2020).
 689 VNRX-5133 (taniborbactam), a broadspectrum inhibitor of serine- and metallo- β -lactamases, restores
 690 activity of cefepime in *Enterobacterales* and *Pseudomonas aeruginosa*. *Antimicrob. Agents*
 691 *Chemother.* 64(3):e01963-19. doi: 10.1128/AAC.01963-19.
- 692 Hauser, R. A. and Ozer, A. E. (2011). *Pseudomonas aeruginosa*. *Nature Review Microbiology* 9 (3).
- 693 Jault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y. A., Resch, G. et al. (2019). Efficacy and
 694 tolerability of a cocktail of bacteriophages to treat burn wounds infected by *Pseudomonas aeruginosa*
 695 (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. *Lancet Infect. Dis.* 19(1):35-45.
 696 doi: 10.1016/S1473-3099(18)30482-1.
- 697 Jean, S. S., Chang, Y. C., Lin, W. C., Lee, W. S., Hsueh, P. R., Hsu, C. W. (2020). Epidemiology,
 698 Treatment, and Prevention of Nosocomial Bacterial Pneumonia. *J. Clin. Med.* 9(1):275. doi:
 699 10.3390/jcm9010275.
- 700 Johansen, H. K. and Gøtzsche, P. C. (2015). Vaccines for preventing infection with *Pseudomonas*
 701 *aeruginosa* in cystic fibrosis. *Cochrane Database Syst. Rev.* 2015(8):CD001399. doi:
 702 10.1002/14651858.
- 703 Jurado-Martín, I., Sainz-Mejías, M., McClean, S. (2021). *Pseudomonas aeruginosa*: An Audacious
 704 Pathogen with an Adaptable Arsenal of Virulence Factors. *Int. J. Mol. Sci.* 22(6):3128. doi:
 705 10.3390/ijms22063128.
- 706 Krammer, F. (2020). SARS-CoV-2 vaccines in development. *Nature* 586(7830):516-527. doi:
 707 10.1038/s41586-020-2798-3
- 708 Lakemeyer, M., Zhao, W., Mandl, F. A., Hammann, P., Sieber, S. A. (2018). Thinking Outside the
 709 Box-Novel Antibacterials To Tackle the Resistance Crisis. *Angew Chem. Int. Ed. Engl.* 57(44):14440-
 710 14475. doi: 10.1002/anie.201804971.
- 711 Lashua, L. P., Melvin, J. A., Deslouches, B., Pilewski, J. M., Montelaro, R. C., Bomberger, J. M. (2016)
 712 Engineered cationic antimicrobial peptide (eCAP) prevents *Pseudomonas aeruginosa* biofilm growth
 713 on airway epithelial cells. *J. Antimicrob. Chemother.* 71(8):2200-7. doi: 10.1093/jac/dkw143.
- 714 Leitner, L., Ujmajuridze, A., Chanishvili, N., Goderdzishvili, M., Chkonia, I., Rigvava, S. et al. (2021).
 715 Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral
 716 resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. *Lancet Infect*
 717 *Dis.* 21(3):427-436 doi: 10.1016/S1473-3099(20)30330-3.
- 718 Lepak, A. J., Wang, W., Andes, D. R. (2020). Pharmacodynamic Evaluation of MRX-8, a Novel
 719 Polymyxin, in the Neutropenic Mouse Thigh and Lung Infection Models against Gram-Negative
 720 Pathogens. *Antimicrob. Agents Chemother.* 64(11):e01517-20. doi: 10.1128/AAC.01517-20.
- 721 Li, J., L. Nation, R., Kaye, K. S. (2019). Polymyxin Antibiotics: From Laboratory Bench to Bedside.
 722 *Advances in Experimental Medicine and Biology* 1145.
- 723 Liu, B., Trout, R. E. L., Chu, G. H., McGarry, D., Jackson, R. W., Hamrick, J. C. et al. (2020).
 724 Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo- β -lactamase

- inhibitor for carbapenem-resistant bacterial infections. *J. Med. Chem.* 63(6):2789-2801. doi: 10.1021/acs.jmedchem.9b01518.
- Lomovskaya, O., Tsivkovski, R., Sun, D., Reddy, R., Totrov, M., Hecker, S. et al. (2021). QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. *Front. Microbiol.* 12:697180. doi: 10.3389/fmicb.2021.697180.
- López-Siles, M., Corral-Lugo, A., McConnell, M. J. (2021). Vaccines for multidrug resistant Gram negative bacteria: lessons from the past for guiding future success. *FEMS Microbiol. Rev.* 45(3):fuaa054. doi: 10.1093/femsre/fuaa054.
- Lu, Q., Rouby, J. J., Laterre, P. F., Eggimann, P., Dugard, A., Giamarellos-Bourboulis, E. J. et al. (2011). Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial *Pseudomonas aeruginosa* O11 pneumonia. *J. Antimicrob. Chemother.* 66(5):1110-6. doi: 10.3390/antibiotics9040155.
- Lucasti, C., Vasile, L., Sandesc, D., Venskutonis, D., McLeroth, P., Lala, M. et al. (2016). Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. *Antimicrob Agents Chemother.* 60(10):6234-43. doi: 10.1128/AAC.00633-16.
- MacNair, C. R., Tsai, C. N., Brown, E. D. (2020). Creative targeting of the Gram-negative outer membrane in antibiotic discovery. *Ann. N. Y. Acad. Sci.* 1459(1):69-85. doi: 10.1111/nyas.14280.
- Martin-Loeches, I., Dale, G. E., Torres, A. (2018). Murepavadin: a new antibiotic class in the pipeline. *Expert Rev. Anti Infect. Ther.* 16(4):259-268. doi: 10.1080/14787210.2018.1441024.
- Merakou, C., Schaefer, M. M., Priebe, G. P. (2018) Progress Toward the Elusive *Pseudomonas aeruginosa* Vaccine. *Surg. Infect. (Larchmt)* 19(8):757-768. doi: 10.1089/sur.2018.233.
- Micoli, F., Bagnoli, F., Rappuoli, R., Serruto, D. (2021). The role of vaccines in combatting antimicrobial resistance. *Nat. Rev. Microbiol.* 1–16. doi: 10.1038/s41579-020-00506-3.
- Montravers, P., Yung, S., Tran-Dinh, A. (2020). A spotlight on the treatment of intraabdominal infections. *Expert Rev. Clin. Pharmacol.* 13(5):469-472. doi: 10.1080/17512433.2020.1766963.
- Moradali, M. F., Ghods, S., Rehm, B. H. (2017). *Pseudomonas aeruginosa* Lifestyle: A Paradigm for Adaptation, Survival, and Persistence. *Front Cell. Infect. Microbiol.* 7:39. doi: 10.3389/fcimb.2017.00039.
- Motsch, J., Murta de Oliveira, C., Stus, V. et al. (2020). RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. *Clin. Infect. Dis.* 70(9):1799-1808. doi: 10.1093/cid/ciz530.
- Mulcahy, L. R., Isabella, V. M., Lewis, K. (2014). *Pseudomonas aeruginosa* biofilms in disease. *Microb. Ecol.* 68(1):1-12. doi: 10.1007/s00248-013-0297-x.
- Newman, J. W., Floyd, R. V., Fothergill, J. L. (2017). The contribution of *Pseudomonas aeruginosa* virulence factors and host factors in the establishment of urinary tract infections. *FEMS Microbiol. Lett.* 364(15). doi: 10.1093/femsle/fnx124.
- Nolan, L. M., Cain, A. K., Clamens, T., Furniss, R. C. D., Manoli, E., Sainz-Polo, M. A., et al. (2021). Identification of Tse8 as a Type VI secretion system toxin from *Pseudomonas aeruginosa* that targets

- the bacterial transamidosome to inhibit protein synthesis in prey cells. *Nat. Microbiol.* 6(9):1199-1210. doi: 10.1038/s41564-021-00950-8.
- Pang, Z., Raudonis, R., Glick, B. R., Lin, T. J., Cheng, Z. (2019). Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol. Adv.* 37(1):177-192. doi: 10.1016/j.biotechadv.2018.11.013.
- Patil, A., Banerji, R., Kanojiya, P., Koratkar, S., Saroj, S. (2021). Bacteriophages for ESKAPE: role in pathogenicity and measures of control. *Expert Rev. Anti. Infect. Ther.* 1-21. doi: 10.1080/14787210.2021.1858800.
- Portsmouth, S., van Veenhuyzen, D., Echols, R., Machida, M., Ferreira, J. C. A., Ariyasu, M., Tenke, P. et al. (2018). Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. *Lancet Infect. Dis.* 18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1.
- Powell, L. C., Pritchard, M. F., Ferguson, E. L., Powell, K. A., Patel, S. U., Rye, P. D. et al. (2018). Targeted disruption of the extracellular polymeric network of *Pseudomonas aeruginosa* biofilms by alginate oligosaccharides. *NPJ Biofilms Microbiomes* 4:13. doi: 10.1038/s41522-018-0056-3.
- Ramireddy, S., Gudipati, S., Zervos, M. (2020). Expect the Unexpected: A Rare Case of *Pseudomonas aeruginosa* Endocarditis. *IDCases.* 12;21:e00787. doi: 10.1016/j.idcr.2020.e00787.
- Rello, J., Krenn, C. G., Locker, G., Pilger, E., Madl C, Balica L, et al. (2017). A randomized placebo-controlled phase II study of a *Pseudomonas* vaccine in ventilated ICU patients. *Crit. Care.* 21(1):22. doi: 10.1186/s13054-017-1601-9.
- Rogan, M. P., Taggart, C. C., Greene, C. M., Murphy, P. G., O'Neill, S. J., McElvaney, N. G. (2004). Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. *J. Infect. Dis.* 190(7):1245-53. doi: 10.1086/423821.
- Roy, P. H., Tetu, S. G., Larouche, A., Elbourne, L., Tremblay, S., Ren Q. et al. (2010). Complete genome sequence of the multiresistant taxonomic outlier *Pseudomonas aeruginosa* PA7. *PLoS One.* 2010 Jan 22;5(1):e8842. doi: 10.1371/journal.pone.0008842.
- Ryder, C., Byrd, M., Wozniak, D. J. (2007). Role of polysaccharides in *Pseudomonas aeruginosa* biofilm development. *Curr. Opin. Microbiol.* 10(6):644-8. doi: 10.1016/j.mib.2007.09.010.
- Sainz-Mejías, M., Jurado-Martín, I., McClean, S. (2020). Understanding *Pseudomonas aeruginosa*-Host Interactions: The Ongoing Quest for an Efficacious Vaccine. *Cells.* 9(12):2617. doi: 10.3390/cells9122617.
- Salunkhe, P., Smart, C. H., Morgan, J. A., Panagea, S., Walshaw, M. J., Hart, C. A. (2005). A cystic fibrosis epidemic strain of *Pseudomonas aeruginosa* displays enhanced virulence and antimicrobial resistance. *J. Bacteriol.* 187(14):4908-20. doi: 10.1128/JB.187.14.4908-4920.2005.
- Sana, T. G., Berni, B., Bleves, S. (2016). The T6SSs of *Pseudomonas aeruginosa* Strain PAO1 and Their Effectors: Beyond Bacterial-Cell Targeting. *Front. Cell. Infect. Microbiol.* 6:61. doi: 10.3389/fcimb.2016.00061.
- Sato, H., and Frank, D. W. (2011). Multi-Functional Characteristics of the *Pseudomonas aeruginosa* Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria. *Front. Microbiol.* 2:142. doi: 10.3389/fmicb.2011.00142.

- 805 Sharland, M., Pulcini, C., Harbarth, S., Zeng, M., Gandra, S., Mathur, S. et al. (2018). 21st WHO
 806 Expert Committee on Selection and Use of Essential Medicines. Classifying antibiotics in the WHO
 807 Essential Medicines List for optimal use-be AWARe. *Lancet Infect. Dis.* 18(1):18-20. doi:
 808 10.1016/S1473-3099(17)30724-7.
- 809 Sheremet, A. B., Zigangirova, N. A., Zayakin, E. S., Luyksaar, S. I., Kapotina, L. N., Nesterenko, L.
 810 N. et al. (2018). Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-
 811 disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an
 812 Airway *Pseudomonas aeruginosa* Infection in Mice. *Biomed. Res. Int.* 2018:5810767. doi:
 813 10.1155/2018/5810767.
- 814 Shrestha, G. S., Vijay, A. K., Stapleton, F., Henriquez, F. L., Carnt, N. (2021). Understanding clinical
 815 and immunological features associated with *Pseudomonas* and *Staphylococcus* keratitis. *Cont. Lens.*
 816 *Anterior Eye* 44(1):3-13. doi: 10.1016/j.clae.2020.11.014.
- 817 Shukla, S. D., Walters, E. H., Simpson, J. L., Keely, S., Wark, P. A. B., O'Toole, R. F. et al. (2020).
 818 Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease.
 819 *Respirology*. 25(1):53-63. doi: 10.1111/resp.13722.
- 820 Sims, M., Mariyanovski, V., McLeroth, P., Akers, W., Lee, Y. C., Brown, M. L. et al. (2017).
 821 Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of
 822 imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated
 823 urinary tract infections. *J. Antimicrob. Chemother.* 72(9):2616-2626. doi: 10.1093/jac/dkx139.
- 824 Smith, J. R., Rybak, J. M., Claeys, K. C. (2020). Imipenem-Cilastatin-Relebactam: A Novel β -Lactam-
 825 β -Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative
 826 Infections. *Pharmacotherapy* 40(4):343-356. doi: 10.1002/phar.2378.
- 827 Tabor, D. E., Oganessian, V., Keller, A. E., Yu, L., McLaughlin, R. E., Song, E. et al. (2018).
 828 *Pseudomonas aeruginosa* PcrV and Psl, the Molecular Targets of Bispecific Antibody MEDI3902, Are
 829 Conserved Among Diverse Global Clinical Isolates. *J. Infect. Dis.* 218(12):1983-1994. doi:
 830 10.1093/infdis/jiy438.
- 831 Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet D. L., et al. (2018). WHO
 832 Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the
 833 WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet. Infect. Dis.* 18(3):318-327.
 834 doi: 10.1016/S1473-3099(17)30753-3.
- 835 Thi, M. T. T., Wibowo, D., Rehm, B. H. A. (2020). *Pseudomonas aeruginosa* Biofilms. *Int. J. Mol.*
 836 *Sci.* 21(22):8671. doi: 10.3390/ijms21228671.
- 837 Theuretzbacher, U., Gottwalt, S., Beyer, P., Butler, M., Czaplewski, L., Lienhardt, C. et al. (2019).
 838 Analysis of the clinical antibacterial and antituberculosis pipeline. *Lancet Infect. Dis.* 19(2):e40-
 839 e50. doi: 10.1016/S1473-3099(18)30513-9.
- 840 Theuretzbacher, U., Bush, K., Harbarth, S., Paul, M., Rex, J. H., Tacconelli, E. et al. (2020). Critical
 841 analysis of antibacterial agents in clinical development. *Nat. Rev. Microbiol.* 18(5):286-298. doi:
 842 10.1038/s41579-020-0340-0.
- 843 Theuretzbacher, U., Outterson, K., Engel, A., Karlén, A. (2020). The global preclinical antibacterial
 844 pipeline. *Nat. Rev. Microbiol.* 18(5):275-285.

- 845 Thomas, E. L. and Aune, T. M. (1978). Lactoperoxidase, peroxide, thiocyanate antimicrobial system:
846 correlation of sulfhydryl oxidation with antimicrobial action. *Infect. Immun.* 20(2):456-63. doi:
847 10.1086/423821.
- 848 Thomsen, K., Christophersen, L., Bjarnsholt, T., Jensen, P. Ø., Moser, C., Høiby, N. (2016). Anti-
849 *Pseudomonas aeruginosa* IgY antibodies augment bacterial clearance in a murine pneumonia model.
850 *J. Cyst. Fibros.* 15(2):171-8. doi: 10.1016/j.jcf.2015.08.002.
- 851 Titov, I., Wunderink, R. G., Roquilly, A., Rodríguez Gonzalez, D., David-Wang, A., Boucher, H. W.
852 et al. (2020). A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of
853 Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or
854 Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). *Clin. Infect. Dis.* 73(11):e4539-
855 e4548. doi: 10.1093/cid/ciaa803.
- 856 Tse, B. N., Adalja, A. A., Houchens, C., Larsen, J., Inglesby, T. V., Hatchett, R. (2017). Challenges
857 and Opportunities of Nontraditional Approaches to Treating Bacterial Infections. *Clin. Infect. Dis.*
858 65(3):495-500. doi: 10.1093/cid/cix320.
- 859 Tümmeler, B. (2019). Emerging therapies against infections with *Pseudomonas aeruginosa*. *F1000Res.*
860 8:F1000 Faculty Rev-1371. doi: 10.12688/f1000research.19509.1.
- 861 Tunney, M. M., Payne, J. E., McGrath, S.J, Einarsson, G. G., Ingram, R. J., Gilpin, D. F. (2018).
862 Activity of hypothiocyanite and lactoferrin (ALX-009) against respiratory cystic fibrosis pathogens in
863 sputum. *J. Antimicrob. Chemother.* 73(12):3391-3397. doi: 10.1093/jac/dky357.
- 864 VanDevanter, D. R. and Chmiel, J. F. (2018). KB001-A, a novel anti-inflammatory, found to be safe
865 and well-tolerated in cystic fibrosis patients infected with *Pseudomonas aeruginosa*. *J. Cyst. Fibros.*
866 17(4):484-491. doi: 10.1016/j.jcf.2017.12.006.
- 867 Van Koningsbruggen-Rietschel, S., Davies, J. C., Pressler, T., Fischer, R., MacGregor, G., Donaldson,
868 S. H. (2020). Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-
869 blind, placebo-controlled, crossover phase 2b study. *ERJ Open Res.* 6(4):00132-2020. doi:
870 10.1183/23120541.00132-2020.
- 871 Vieira Colombo, A. P., Magalhães, C. B., Hartenbach, F. A., Martins do Souto, R., Maciel da Silva-
872 Boghossian, C. (2016). Periodontal-disease-associated biofilm: A reservoir for pathogens of medical
873 importance. *Microb. Pathog.* 94:27-34. doi: 10.1016/j.micpath.2015.09.009.
- 874 WHO, World Health Organization (2019). 2019 Antibacterial agents in clinical development: an
875 analysis of the antibacterial clinical development pipeline.
876 <https://www.who.int/publications/i/item/9789240000193>
- 877 WHO, World Health Organization (2020). 2020 Antibacterial agents in clinical and preclinical
878 development: an overview and analysis. <https://www.who.int/publications/i/item/9789240021303>
- 879 Wu, D. C., Chan, W. W., Metelitsa, A. I., Fiorillo, L., Lin, A. N. (2011). *Pseudomonas* skin infection:
880 clinical features, epidemiology, and management. *Am. J. Clin. Dermatol.* 12(3):157-69. doi:
881 10.2165/11539770-000000000-00000.
- 882 Wunderink, R. G. , Matsunaga, Y., Ariyasu, M., Clevenbergh, P., Echols, R, Kaye, KS, et al. (2021).
883 Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative

- 884 nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
885 Lancet Infect. Dis. 21(2):213-225. doi: 10.1016/S1473-3099(20)30731-3
- 886 Yaeger, L. N., Coles, V. E., Chan, D. C. K., Burrows, L. L. (2021). How to kill *Pseudomonas*-emerging
887 therapies for a challenging pathogen. Ann. N. Y. Acad. Sci. 1496(1):59-81. doi: 10.1111/nyas.14596.
- 888 Zhang, Y., Pan, X., Wang L., Chen. L. et al. (2021). Iron metabolism in *Pseudomonas*
889 *aeruginosa* biofilm and the involved iron-targeted anti-biofilm strategies. J. Drug Target. 29(3):249-
890 258. doi: 10.1080/1061186X.2020.1824235.
- 891 Zurawski, D. V., McLendon, M. K. (2020). Monoclonal Antibodies as an Antibacterial Approach
892 Against Bacterial Pathogens. Antibiotics (Basel) 9(4):155.